Fundamentals Hub
BCTX BriaCell Therapeutics Corp.
BCTX financial statements, revenue, balance sheet, cash flow, and SEC filings
Showing 3 of 5 annual and 0 of 19 quarterly periods.
Full history available with a free account or via API.
▼ Company Profile
Filer Category
<br>Emerging growth company
Entity Type
Operating
Public Float
$94.48M (Jan 2025)
Industry (SIC)
2834 Pharmaceutical Preparations
Incorporated
A1
Fiscal Year End
July (0731)
Phone
(604) 921-1810
EIN
000000000
Headquarters
WEST VANCOUVER, A1, V7T 2X1
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.
Former Names:
Ansell Capital Corp. (2014–2014)
▼ Key Metrics (TTM)
As of Apr 30, 2026Financials
Revenue
-
Net Income
$-30.68M
Total Assets
$27.07M
Total Equity
$23.41M
Total Debt
-
Free Cash Flow
-
Ratios
Return on Equity
-131%
Return on Assets
-113.3%
Current Ratio
7.07x
Sources and calculation details
Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.
Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.
Annual (FY)
Quarterly 🔒
Chart 🔒
| Metric | FY2025 📄 | FY2024 📄 | FY2023 📄 |
|---|---|---|---|
| Income Statement | |||
| REVENUE | |||
| OPERATING EXPENSES | |||
| R&D Expense | $21.27M | $27.18M | $15.34M |
| SG&A Expense | $5.93M | $6.15M | $7.94M |
| Operating Income | $-27.20M | $-33.33M | $-23.27M |
| NON-OPERATING INCOME / EXPENSE | |||
| Interest Income | $119.96K | $288.02K | $891.21K |
| Other Income/Expense | $114.51K | $262.57K | $850.34K |
| Pretax Income | $26.56M | $4.93M | $20.30M |
| Net Income | $-26.31M | $-4.79M | $-20.30M |
| PER SHARE & SUPPLEMENTAL | |||
| Diluted EPS | $-62.19 | $-43.68 | $-1.30 |
| Diluted Shares | 423.11K | 109.70K | 15.62M |
| EBITDA | $-27.11M | $-33.26M | - |
| Depreciation & Amortization | $91.36K | $68.63K | - |
| Balance Sheet | |||
| ASSETS | |||
| Cash & Equivalents | $10.49M | $862.09K | $21.25M |
| Short-term Investments | $7.37M | - | - |
| Accounts Receivable | - | - | $18.87K |
| Other Current Assets | $1.39M | $1.32M | $4.84M |
| Current Assets | $19.93M | $3.65M | $26.95M |
| PP&E (Net) | $296.82K | $388.18K | $2.50K |
| Intangible Assets | $184.53K | $199.80K | $215.07K |
| Noncurrent Assets | $1.72M | $2.22M | $215.07K |
| Total Assets | $21.65M | $5.87M | $27.16M |
| LIABILITIES | |||
| Current Liabilities | $3.98M | $7.46M | $1.80M |
| Noncurrent Liabilities | $337.67K | $1.10M | $29.14M |
| Total Liabilities | $4.32M | $8.56M | $30.94M |
| EQUITY | |||
| Common Stock | $101.74M | $72.17M | $69.59M |
| Retained Earnings | $-111.76M | $-85.44M | $-80.65M |
| Accumulated OCI | $-138.68K | $-138.68K | $-138.68K |
| Total Equity | $17.33M | $-2.68M | $-3.78M |
| Total Liabilities & Equity | $21.65M | $5.87M | $27.16M |
| SUPPLEMENTAL | |||
| Shares Outstanding | 1.88M | 121.91K | 15.98M |
| Check: A − (L + E + NCI) | - | - | - |
| Cash Flow Statement | |||
| Cash from Operations | $-28.17M | $-24.13M | $-23.74M |
| Capital Expenditures | - | $456.80K | - |
| Cash from Investing | $-7.65M | $-681.80K | - |
| Cash from Financing | $45.45M | $4.42M | $3.95M |
| Free Cash Flow | - | $-24.58M | - |
| Beginning Cash (CFS) | $862.09K | $21.25M | - |
| Net Change in Cash | $9.63M | $-20.39M | - |
| Effect of FX on Cash | - | - | - |
| Calculated Ending Cash | $10.49M | $862.09K | - |
| Cash per BS | $10.49M | $862.09K | $21.25M |
| Cash scope difference (CFS − BS) | - | - | - |
| Cash per CFS | $10.49M | $862.09K | $21.25M |
Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.
Create Free Account Log In🔒
Quarterly data and charts require a free account
Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.
▼ Frequently Asked Questions
Is BriaCell Therapeutics Corp. profitable?
No. BriaCell Therapeutics Corp. reported $-30.68M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.